Dr. Nagaraj Kulkarni

Research

Publications

Two decades of work on metabolic disease, inflammation, oncology and AI-driven drug discovery, in papers, preprints and patents.

Find me elsewhere

  • 698citations
  • 16h-index
  • 17i10-index

Citation figures are from Google Scholar as of October 2026. Preprints and duplicate records are listed once. Names in bold are mine.

Journal articles 22

2026

  1. AI-driven discovery and validation of a GIPC1 PDZ domain inhibitor for pancreatic ductal adenocarcinoma

    Rachamala HK, Rao Nakka NM, Angom RS, Varanasi SM, Wei F, Kulkarni T, Dutta SK, Wang E, Kulkarni NM, Ben Geoffrey AS, Hegde SP, Perumal S, Gurram K, Gharibi H, Gaetani M, Mukherjee SP, Babiker H, Pal K, Mukhopadhyay D

    Cell Reports 45(8):117777. doi:10.1016/j.celrep.2026.117777

2025

  1. Molecular Glue-Design-Evaluator (MOLDE): an advanced method for in-silico molecular glue design

    Ben Geoffrey AS, Agrawal D, Kulkarni NM, Gunasekaran M

    ACS Omega 10(7):6650-6662. doi:10.1021/acsomega.4c08049

  2. Correction to “Molecular Glue-Design-Evaluator (MOLDE): an advanced method for in-silico molecular glue design”

    Ben Geoffrey AS, Agrawal D, Kulkarni NM, Gunasekaran M

    ACS Omega 10(21):22296. doi:10.1021/acsomega.5c01516

2024

  1. PROTAC-Design-Evaluator (PRODE): an advanced method for in-silico PROTAC design

    Ben Geoffrey AS, Agrawal D, Kulkarni NM, Vetrivel R, Gurram K

    ACS Omega 9(11):12611-12621. doi:10.1021/acsomega.3c07318

2021

  1. STE20-type protein kinase MST4 controls NAFLD progression by regulating lipid droplet dynamics and metabolic stress in hepatocytes

    Caputo M, Cansby E, Kumari S, Kurhe Y, Nair S, Ståhlman M, Kulkarni NM, Borén J, Marschall H, Blüher M, Mahlapuu M

    Hepatology Communications 5(7):1183-1200. doi:10.1002/hep4.1702

2020

  1. Depletion of protein kinase STK25 ameliorates renal lipotoxicity and protects against diabetic kidney disease

    Cansby E, Caputo M, Gao L, Kulkarni NM, Nerstedt A, Ståhlman M, Borén J, Porosk R, Soomets U, Pedrelli M, Parini P, Marschall HU, Nyström J, Howell BW, Mahlapuu M

    JCI Insight 5(24):e140483. doi:10.1172/jci.insight.140483

  2. High fat worsens olanzapine induced metabolic abnormalities in rats

    Jamaluddin SJ, Nilugal KC, Kulkarni NM, Fattepur S, Abdullah I, Ugandar RE

    British Food Journal 122(10):3065-3075. doi:10.1108/bfj-02-2020-0121

2019

  1. Protein kinase MST3 modulates lipid homeostasis in hepatocytes and correlates with nonalcoholic steatohepatitis in humans

    Cansby E, Kulkarni NM, Magnusson E, Kurhe Y, Amrutkar M, Nerstedt A, Ståhlman M, Sihlbom C, Marschall H, Borén J, Blüher M, Mahlapuu M

    The FASEB Journal 33(9):9974-9989. doi:10.1096/fj.201900356rr

  2. Targeted delivery of Stk25 antisense oligonucleotides to hepatocytes protects mice against nonalcoholic fatty liver disease

    Cansby E, Nuñez-Durán E, Magnusson E, Amrutkar M, Booten SL, Kulkarni NM, Svensson LT, Borén J, Marschall HU, Aghajan M, Mahlapuu M

    Cellular and Molecular Gastroenterology and Hepatology 7(3):597-618. doi:10.1016/j.jcmgh.2018.12.004

2018

  1. STK25 regulates oxidative capacity and metabolic efficiency in adipose tissue

    Sütt S, Cansby E, Paul A, Amrutkar M, Nuñez-Durán E, Kulkarni NM, Ståhlman M, Borén J, Laurencikiene J, Howell BW, Enerbäck S, Mahlapuu M

    Journal of Endocrinology 238(3):187-202. doi:10.1530/joe-18-0182

2017

  1. Terminalia chebula Retz. – an important medicinal plant

    Kolla JN, Kulkarni NM, Kura RR, Theepireddy SKR

    Herba Polonica 63(4):45-56. doi:10.1515/hepo-2017-0024

  2. Enhanced anticancer efficacy of histone deacetyl inhibitor, suberoylanilide hydroxamic acid, in combination with a phosphodiesterase inhibitor, pentoxifylline, in human cancer cell lines

    Nidhyanandan S, Thippeswamy BS, Chandrasekhar KB, Reddy ND, Kulkarni NM, Karthikeyan K, Khan FR, Raghul J, Vijaykanth G, Narayanan S

    Anti-Cancer Drugs 28(9):1002-1017. doi:10.1097/cad.0000000000000544

2016

  1. Altered pharmacokinetics of rosiglitazone in a mouse model of non-alcoholic fatty liver disease

    Kulkarni NM, Malampati S, Mahat MYA, Chandrasekaran S, Raghul J, Khan AA, Krishnan UM, Narayanan S

    Drug Metabolism and Personalized Therapy 31(3):165-171. doi:10.1515/dmpt-2016-0008

  2. Subacute toxicity of gallic acid, isolated from Terminalia chebula, in Swiss albino mice

    Theepireddy DMSKR, Kulkarni NM, Chinthala R, et al.

    International Journal of Chemistry and Pharmaceutical Sciences 4(10):439-443.

2015

  1. Phosphodiesterase inhibitor, pentoxifylline enhances anticancer activity of histone deacetylase inhibitor, MS-275 in human breast cancer in vitro and in vivo

    Nidhyanandan S, Boreddy TS, Chandrasekhar KB, Reddy ND, Kulkarni NM, Narayanan S

    European Journal of Pharmacology 764:508-519. doi:10.1016/j.ejphar.2015.07.048

  2. A novel animal model of metabolic syndrome with non-alcoholic fatty liver disease and skin inflammation

    Kulkarni NM, Jaji MS, Shetty P, Kurhe YV, Chaudhary S, Vijaykant G, Raghul J, Vishwakarma SL, Rajesh BN, Mookkan J, Krishnan UM, Narayanan S

    Pharmaceutical Biology 53(8):1110-1117. doi:10.3109/13880209.2014.960944

  3. Topical atorvastatin ameliorates 12-O-tetradecanoylphorbol-13-acetate induced skin inflammation by reducing cutaneous cytokine levels and NF-κB activation

    Kulkarni NM, Muley MM, Jaji MS, Vijaykanth G, Raghul J, Reddy NKD, Vishwakarma SL, Rajesh NB, Mookkan J, Krishnan UM, Narayanan S

    Archives of Pharmacal Research 38(6):1238-1247. doi:10.1007/s12272-014-0496-0

2014

  1. Combination of vildagliptin and rosiglitazone ameliorates nonalcoholic fatty liver disease in C57BL/6 mice

    Mookkan J, De S, Shetty P, Kulkarni NM, Devisingh V, Jaji MS, Lakshmi V, Chaudhary S, Kulathingal J, Rajesh N, Narayanan S

    Indian Journal of Pharmacology 46(1):46. doi:10.4103/0253-7613.125166

2011

  1. Embelin reduces cutaneous TNF-α level and ameliorates skin edema in acute and chronic model of skin inflammation in mice

    Kumar GK, Dhamotharan R, Kulkarni NM, Mahat MYA, Gunasekaran J, Ashfaque M

    European Journal of Pharmacology 662(1-3):63-69. doi:10.1016/j.ejphar.2011.04.037

  2. Embelin ameliorates dextran sodium sulfate-induced colitis in mice

    Kumar GK, Dhamotharan R, Kulkarni NM, Honnegowda S, Murugesan S

    International Immunopharmacology 11(6):724-731. doi:10.1016/j.intimp.2011.01.022

2010

  1. Modulation of the cyclooxygenase pathway via inhibition of nitric oxide production contributes to the anti-inflammatory activity of kaempferol

    Mahat MYA, Kulkarni NM, Vishwakarma SL, Khan FR, Thippeswamy BS, Hebballi V, Adhyapak AA, Benade VS, Ashfaque SM, Tubachi S, Patil BM

    European Journal of Pharmacology 642(1-3):169-176. doi:10.1016/j.ejphar.2010.05.062

2006

  1. Elevation of systolic blood pressure in an animal model of olanzapine induced weight gain

    Patil BM, Kulkarni NM, Unger BS

    European Journal of Pharmacology 551(1-3):112-115. doi:10.1016/j.ejphar.2006.09.009

Preprints 3

  1. DMPKformer: an interpretable multimodal deep learning framework for reliable ADMET property prediction

    Singh A, Kanchan S, Anapat S, Gurram K, Kulkarni NM, Ben Geoffrey AS

    bioRxiv (preprint). doi:10.64898/2026.05.28.728612

  2. An in-silico approach for novel molecular glue design by rationalizing known molecular glue mediated ternary complex formation

    Ben Geoffrey AS, Kulkarni NM, Agrawal D, Bharti N, Vetrivel R, Gurram K

    bioRxiv (preprint), 2022.10.04.510266. doi:10.1101/2022.10.04.510266

  3. A new in-silico approach for PROTAC design and quantitative rationalization of PROTAC mediated ternary complex formation

    Ben Geoffrey AS, Kulkarni NM, Agrawal D, Vetrivel R, Gurram K

    bioRxiv (preprint), 2022.07.11.499663. doi:10.1101/2022.07.11.499663

Patents 2

  1. Formulation and a method of treating carcinoma

    Kulkarni N, Baskaran B, Samraj BGA, Bhagavat R, Gurram K, et al.

    US Patent Application 19/366,141.

  2. Inhibitors of ectonucleotide pyrophosphatase / phosphodiesterase 1 (ENPP-1)

    Ramanarayanan GBV, Saravanan P, Saravanan V, Nagaraj K

    WO Patent WO2024127343A1.

Chapters, abstracts and thesis 7

  1. Metabolic syndrome, non-alcoholic fatty liver disease (NAFLD) and psoriasis

    Kulkarni NM, Krishnan UM, Narayanan S

    In: Liver Disease: Diagnosis, Treatment and Management, pp. 45-72, 2016 (chapter).

  2. Development of a new rat model of non-alcoholic fatty liver disease with insulin resistance and obesity

    Narayanan S, Jaji MS, Devisingh V, Kulkarni NM, Navinrajesh B, et al.

    Diabetes 61:A270, 2012 (abstract).

  3. Effect of BLX-1002 in a rat model of non-alcoholic fatty liver disease

    Mookkan J, Kulathingal J, Jaji MS, Devisingh V, Kulkarni NM, et al.

    Diabetes 61:A250, 2012 (abstract).

  4. Combination of vildagliptin and rosiglitazone ameliorates non-alcoholic fatty liver disease in C57BL/6 mice

    Mookkan J, De S, Shetty P, Kulkarni NM, Devisingh V, Jaji MS, et al.

    Diabetes 60:A284, 2011 (abstract).

  5. Effect of BLX 1002 on key features of non-alcoholic fatty liver disease (NAFLD) in animal models

    Narayanan S, Devisingh V, Kulkarni NM, Shetty P, Jaji MS, Rajesh BN, et al.

    Diabetes 60:A288-A289, 2011 (abstract).

  6. Efficacy of BLX 1002 in animal models of non-alcoholic fatty liver disease and dyslipidemia

    Narayanan S, Vijayaraj D, Kulkarni NM, Shetty P, Jayanarayan K, et al.

    Journal of Hepatology 54:S502, 2011 (abstract).

  7. Effect of atypical antipsychotics on hypertension and insulin resistance in fructose fed rats

    Kulkarni N

    Rajiv Gandhi University of Health Sciences, Bangalore, 2006 (thesis).

Looking for a paper?

If a paper is behind a paywall, ask me for a copy by email or find the full text on ResearchGate.

Email me